Cash from Investing (Quarterly) Chart

Historical Cash from Investing (Quarterly) Data

View and export this data back to 1997. Start Trial.
Date Value
September 30, 2026 -2.708M
June 30, 2026 -2.82M
March 31, 2026 -4.201M
December 31, 2025 -16.39M
September 30, 2025 -3.377M
June 30, 2025 -9.028M
March 31, 2025 -15.14M
December 31, 2024 -14.65M
September 30, 2024 -21.21M
June 30, 2024 -17.72M
March 31, 2024 -25.45M
December 31, 2023 -8.088M
September 30, 2023 4.566M
June 30, 2023 -2.408M
March 31, 2023 2.80M
December 31, 2022 -21.73M
September 30, 2022 -0.811M
June 30, 2022 -2.997M
March 31, 2022 -10.67M
December 31, 2021 1.885M
September 30, 2021 -2.629M
June 30, 2021 -14.94M
March 31, 2021 12.19M
December 31, 2020 -25.68M
September 30, 2020 -17.44M
Date Value
June 30, 2020 12.21M
March 31, 2020 13.74M
December 31, 2019 -14.60M
September 30, 2019 13.37M
June 30, 2019 -3.811M
March 31, 2019 15.66M
December 31, 2018 -20.45M
September 30, 2018 -45.60M
June 30, 2018 -0.795M
March 31, 2018 -0.184M
December 31, 2017 -0.718M
September 30, 2017 -0.519M
June 30, 2017 -0.203M
March 31, 2017 -0.07M
December 31, 2016 -0.101M
September 30, 2016 -0.333M
June 30, 2016 -1.061M
March 31, 2016 0.08M
December 31, 2015 -0.097M
September 30, 2015 -0.775M
June 30, 2015 -1.202M
March 31, 2015 -0.318M
December 31, 2014 -0.646M
September 30, 2014 -2.568M
June 30, 2014 1.036M

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. -86.15M
Alnylam Pharmaceuticals, Inc. -311.74M
Anika Therapeutics, Inc. -1.756M
Savara, Inc. 31.01M
Arrowhead Pharmaceuticals, Inc. 203.86M